Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Jonathan N. King"'
Autor:
Jonathan N. King, Wolfgang Seewald, Sophie Forster, Gabriele Friton, Derek E. Adrian, B. Duncan X. Lascelles
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 35, Iss 5, Pp 2384-2394 (2021)
Abstract Background Evaluate the clinical safety of robenacoxib in cats with chronic musculoskeletal disease (CMSD). Animals Four hundred forty‐nine client‐owned cats with CMSD. Methods Pooled analysis of safety variables from 4 prospective rando
Externí odkaz:
https://doaj.org/article/4cb94167ea714ae8865b1c2589e697a7
Autor:
Derek Adrian, Jonathan N. King, Rudolph S. Parrish, Stephen B. King, Steven C. Budsberg, Margaret E. Gruen, B. Duncan X. Lascelles
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
Abstract The main objective of this pilot clinical trial was to evaluate outcome measures for the assessment of the nonsteroidal anti-inflammatory drug (NSAID) robenacoxib in cats with degenerative joint disease-associated pain (DJD-pain). Otherwise
Externí odkaz:
https://doaj.org/article/fb60e1d331c4401f95a2359a9659a4cd
Autor:
Jonathan N. King, Mike Martin, Valérie Chetboul, Luca Ferasin, Anne T. French, Günther Strehlau, Wolfgang Seewald, Sarah G. W. Smith, Simon T. Swift, Susan L. Roberts, Andrea M. Harvey, Christopher J. L. Little, Sarah M. A. Caney, Kerry E. Simpson, Andrew H. Sparkes, Eleanor J. Mardell, Eric Bomassi, Claude Muller, John P. Sauvage, Armelle Diquélou, Matthias A. Schneider, Laurence J. Brown, David D. Clarke, Jean‐Francois Rousselot
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 33, Iss 6, Pp 2559-2571 (2019)
Abstract Background Heart disease is an important cause of morbidity and mortality in cats, but there is limited evidence of the benefit of any medication. Hypothesis The angiotensin‐converting enzyme inhibitor benazepril would delay the time to tr
Externí odkaz:
https://doaj.org/article/e01e020d87f342d68c6287473d57527a
Publikováno v:
BMC Veterinary Research, Vol 13, Iss 1, Pp 1-12 (2017)
Abstract Background Non-steroidal anti-inflammatory drugs (NSAIDs) have been proven to be effective in controlling peri-operative pain in dogs. Robenacoxib is an NSAID with high selectivity for the cyclooxygenase (COX)-2 isoform. The objective of thi
Externí odkaz:
https://doaj.org/article/bdecd7e0e0c54824b3c92fca94d0096a
Autor:
Peter Lees, Pierre‐Louis Toutain, Jonathan Elliott, Jerome M. Giraudel, Ludovic Pelligand, Jonathan N. King
Publikováno v:
Journal of Veterinary Pharmacology and Therapeutics. 45:325-351
Robenacoxib is a veterinary-approved non-steroidal anti-inflammatory drug (NSAID) of the coxib group. It possesses anti-hyperalgesic, anti-inflammatory and anti-pyretic properties. Robenacoxib inhibits the cyclooxygenase (COX)-2 isoform of COX select
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4f50bfd337f3c7cfff4d84e4d8b702e
https://doi.org/10.1111/jvp.13052
https://doi.org/10.1111/jvp.13052
Autor:
Derek Adrian, Sophie Forster, Gabriele Friton, Wolfgang Seewald, B. Duncan X. Lascelles, Jonathan N. King
Publikováno v:
Journal of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine, Vol 35, Iss 5, Pp 2384-2394 (2021)
Journal of Veterinary Internal Medicine, Vol 35, Iss 5, Pp 2384-2394 (2021)
Background Evaluate the clinical safety of robenacoxib in cats with chronic musculoskeletal disease (CMSD). Animals Four hundred forty‐nine client‐owned cats with CMSD. Methods Pooled analysis of safety variables from 4 prospective randomized bli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d45d468d792b7a9387bb0bf6b0e3d229
http://europepmc.org/articles/PMC8478032
http://europepmc.org/articles/PMC8478032
Autor:
Margaret E. Gruen, Steven C. Budsberg, Derek Adrian, Stephen King, Jonathan N. King, B. Duncan X. Lascelles, Rudolph S. Parrish
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
Scientific Reports
Scientific Reports
The main objective of this pilot clinical trial was to evaluate outcome measures for the assessment of the nonsteroidal anti-inflammatory drug (NSAID) robenacoxib in cats with degenerative joint disease-associated pain (DJD-pain). Otherwise healthy c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7f407df5f5138171ccd56c1b0f094f1
https://doaj.org/article/fb60e1d331c4401f95a2359a9659a4cd
https://doaj.org/article/fb60e1d331c4401f95a2359a9659a4cd
Autor:
Laurence J Brown, Andrea Harvey, Susan L Roberts, Jean-François Rousselot, David D. Clarke, Simon Swift, John P Sauvage, Andy Sparkes, Wolfgang Seewald, Valérie Chetboul, Eleanor J. Mardell, Mike Martin, C.J.L. Little, Claude Muller, Eric Bomassi, Sarah G W Smith, Anne French, Matthias Schneider, Jonathan N. King, Sarah Caney, Günther Strehlau, L. Ferasin, Kerry E Simpson, Armelle Diquélou
Publikováno v:
Journal of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine, Vol 33, Iss 6, Pp 2559-2571 (2019)
Journal of Veterinary Internal Medicine, 2019, pp.1-13. ⟨10.1111/jvim.15572⟩
Journal of Veterinary Internal Medicine, Wiley, 2019, pp.1-13. ⟨10.1111/jvim.15572⟩
Journal of Veterinary Internal Medicine, 1-13. (2019)
Journal of Veterinary Internal Medicine, Vol 33, Iss 6, Pp 2559-2571 (2019)
Journal of Veterinary Internal Medicine, 2019, pp.1-13. ⟨10.1111/jvim.15572⟩
Journal of Veterinary Internal Medicine, Wiley, 2019, pp.1-13. ⟨10.1111/jvim.15572⟩
Journal of Veterinary Internal Medicine, 1-13. (2019)
© 2019 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine. Background: Heart disease is an important cause of morbidity and mortality in cats, b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d3405a59d9e2e22e2972972864cc2bc
https://doi.org/10.1111/jvim.15572
https://doi.org/10.1111/jvim.15572
Autor:
Martin Jung, Jonathan N. King
Publikováno v:
Journal of veterinary pharmacology and therapeuticsREFERENCES. 44(3)
The objective of the studies was to determine the route of excretion, faecal or urinary, of the nonsteroidal anti-inflammatory drug (NSAID) robenacoxib (Onsior™) in cats and dogs. The studies employed a two-part crossover design in 4 beagle dogs (2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a859e823da08be1e0701fe6c9b3476ff
https://pubmed.ncbi.nlm.nih.gov/33881783
https://pubmed.ncbi.nlm.nih.gov/33881783
Autor:
C. Brovida, A. Font, R.A. Ash, Jean-François Rousselot, Jonathan N. King, D. Lanore, U. Bonfanti, Wolfgang Seewald, D. Pechereau, I.D. Crowe, Günther Strehlau
Publikováno v:
Journal of Veterinary Internal Medicine
Background Chronic kidney disease (CKD) is an important cause of morbidity and mortality in dogs. Objective To evaluate the efficacy in prolonging survival and safety of benazepril administration to dogs with CKD. Animals Forty-nine client-owned dogs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::984c45e2c69b3be18532bbf735447543
http://europepmc.org/articles/PMC5508345
http://europepmc.org/articles/PMC5508345